- Home
- UNCY vs PFO Comparison
UNCY vs PFO Comparison
Compare UNCY & PFO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UNCY | PFO |
|---|---|---|
| Founded | 2016 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.8M | 123.3M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | UNCY | PFO |
|---|---|---|
| Price | $6.96 | $9.21 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $44.50 | N/A |
| AVG Volume (30 Days) | ★ 463.9K | 33.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.51% |
| EPS Growth | ★ 56.25 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $675,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.45 | $8.01 |
| 52 Week High | $7.57 | $9.90 |
Technical Indicators
Market Signals| Indicator | UNCY | PFO |
|---|---|---|
| Relative Strength Index (RSI) | 55.40 | 25.52 |
| Support Level | $5.90 | $9.17 |
| Resistance Level | $7.36 | $9.76 |
| Average True Range (ATR) | 0.36 | 0.09 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 75.76 | 13.21 |
Price Performance
Historical ComparisonAbout UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
About PFO Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated
Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.